Revenue Potential: Apitegromab has a total revenue potential of greater than $1 billion. Scholar Rock Holding Corp ...

H.C. Wainwright raised the firm’s price target on Scholar Rock (SRRK) to $40 from $35 and keeps a Buy rating on the shares. Scholar Rock ...

Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Scholar Rock Holding (SRRK – Research Report). The associated price target was raised to $40.00. Andres Y. Maldonado ...

Scholar Rock Holding Corp (NASDAQ:SRRK) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) has been given a consensus rating of “Buy” by the seven brokerages ...

(The Center Square) – Texans on Tuesday resoundingly reelected U.S. Sen. Ted Cruz and handed the state's 40 Electoral College votes to former President Donald Trump, both Republicans who previously ...

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 28.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 748,489 shares ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...